Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors.
Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated on a phase II trial with topotecan. None of the 14 evaluable patients achieved a complete or partial response. Myelosuppression was the major toxicity. The median nadir leukocyte count was 1.75 cells/mm3, neutrophil count was 1.55 cells/mm3, hemoglobin was 8.75 gm/dl, and platelet count was 20,500 cells/mm3. Topotecan is not efficacious in the treatment of cisplatin-refractory GCT.
Puc
H S
HS
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Bajorin
D F
DF
Bosl
G J
GJ
Amsterdam
A
A
Motzer
R J
RJ
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D018237:Germinoma / Q000188:drug therapy* / Q000556:secondary; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D019772:Topotecan
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D006454:Hemoglobins; D019772:Topotecan; D002945:Cisplatin; D002166:Camptothecin